The National Academy of Medicine AI Code of Conduct

As health AI continues to advance rapidly in both technology and application, the need for common alignment and action to safeguard public health has become increasingly urgent. To that end, the U.S. National Academy of Medicine released the nation’s first AI Code of Conduct for health and medicine. This framework, which includes a set of Principles and Commitments, reflects the field’s leading insights and is designed to help align stakeholders around responsible development and use of health AI. To ground these Commitments in real-world practice, the Academy convened national experts and patient advocates to explore their application across key domains: promoting humanity, ensuring equity, engaging those most affected, supporting workforce well-being, monitoring system performance, and fostering innovation and learning. The resulting special publication, the National Academy of Medicine AI Code of Conduct, is now publicly available.

Laura Adams, Senior Advisor at the National Academy of Medicine (NAM), leads NAM’s Artificial Intelligence Code of Conduct and the NAM Patient Safety in the Era of AI national initiatives. Laura chairs the Global Opportunities Group for The Centre of Excellence for AI Regulatory Science and Innovation in the UK, and she is a strategic advisor for Inflammatix, a Burlingame, CA-based biotech company specializing in host immune response diagnostics. Her expertise is in AI governance, digital health, and human-centered care.

Laura is a member of the international Expert Panel on Health AI for the Organization of Economic Co-operation and Development (OECD); the Bipartisan Policy Center’s Health Care AI Advisory Panel; and the Consumer Technology Association’s Health AI Planning Council. She is recognized as a strategic leader of large scale multisectoral initiatives with a deep experience in and understanding of the complex U.S. health care industry, including how the components function and interact.

Laura was among the first to bring the science of clinical quality improvement to the Middle East, in conjunction with Donald Berwick, MD and the Harvard Institute for Social and Economic Policy in the Middle East. Prior to her work at the NAM, Laura was founding President and CEO of the Rhode Island Quality Institute (RIQI), a living laboratory for advancing health information exchange. Under her leadership, RIQI won the National Council for Community Behavioral Health Excellence Award for Impact on the opioid crisis. Laura has delivered keynotes in nearly every state in the union and in 14 countries worldwide.